Teleflex Launches New Arrow® VPS Rhythm® DLX Device and NaviCurve™ Stylet in the United States
02 Maio 2023 - 7:30AM
Teleflex Incorporated (NYSE: TFX), a leading global provider of
medical technologies, today announced the launch of two new devices
designed to enhance PICC insertion procedures and reduce the chance
of complications. The new Arrow® VPS Rhythm® DLX Device and
NaviCurve™ Stylet are engineered to work together to give Vascular
Access Specialists more efficient and predictable PICC placement.
The next-generation VPS Rhythm® DLX Device
provides real-time catheter tip location information by using the
patient’s cardiac electrical activity. The device is also available
with an optional integrated ultrasound featuring a
Catheter-to-Vessel ratio tool that promotes standardization in
vessel measurement. This device works in concert with the Arrow®
PICC preloaded with the NaviCurve™ Stylet, providing innovative tip
navigation/location technologies.
The VPS Rhythm® DLX Device with TipTracker™
Technology eliminates the need for a confirmatory x-ray, helping
the clinician insert seamlessly through ultrasound vessel
assessment, PICC navigation, to final tip confirmation in the lower
third of the superior vena cava.1
Due to the variability of patient vasculature,
all PICCs can occasionally have difficulty advancing into the
superior vena cava (SVC) on the first attempt. The Arrow®
NaviCurve™ Stylet features an anatomical curve and flexible tip
that are designed to self-orient to patient anatomy for enhanced
PICC advancement into the superior vena cava (SVC) for successful
insertion.1
Teleflex conducted extensive research with
industry-leading vascular access professionals to design the
enhancements featured in the new Arrow® VPS Rhythm® DLX Device,
NaviCurve™ Stylet, PICCS, and other insertion accessories.
Clinician-inspired updates to the portfolio
include:
- Integrated
ultrasound (optional) to assist
with vascular access
- Real-time
visual catheter
navigation, featuring a visualization area twice
the size of the BD Sherlock 3CG™2,3
- In
benchtop testing,
optimal PICC
dropping into
the lower third
of the SVC in
a simulated model, with a
90% drop rate on first insertion attempt with the
NaviCurve™ Stylet compared to 0% drop rate with market leading PICC
from BD1
- Premium
kit components available
including one-piece, full-body fenestrated drape, ultrasound probe
cover with gel, and 3M™Tegaderm™ CHG Securement Dressing
“We remain committed to building strong
partnerships with our clinicians and hospitals, and these latest
advancements in Arrow® Catheter Insertion
Technology from Teleflex align with our mutual goal toward zero
catheter-related complications. The introduction of our new
positioning device and enhanced catheter design complement our
proprietary Arrowg+ard Blue Advance® PICC antimicrobial and
antithrombogenic protection that reduces thrombus accumulation and
the primary pathogens responsible for most healthcare associated
infections.4 With multiple levels of protection, critical
innovations, best-in-class education and bedside support, we are
well suited to be the partner of choice for our customers.” said
Lisa Kudlacz, President and General Manager, Vascular at
Teleflex.
About Teleflex
IncorporatedTeleflex is a global provider of
medical technologies designed to improve the health and quality of
people’s lives. We apply purpose driven innovation – a relentless
pursuit of identifying unmet clinical needs – to benefit patients
and healthcare providers. Our portfolio is diverse, with solutions
in the fields of vascular access, interventional cardiology and
radiology, anesthesia, emergency medicine, surgical, urology and
respiratory care. Teleflex employees worldwide are united in the
understanding that what we do every day makes a difference. For
more information, please visit teleflex.com.
Teleflex is the home of Arrow®, Deknatel®, LMA®,
Pilling®, QuikClot®, Rüsch®, UroLift®, and Weck® – trusted brands
united by a common sense of purpose.
Forward-Looking
StatementsAny statements contained in this press
release that do not describe historical facts may constitute
forward-looking statements. Any forward-looking statements
contained herein are based on our management's current beliefs and
expectations, but are subject to several risks, uncertainties and
changes in circumstances, which may cause actual results or company
actions to differ materially from what is expressed or implied by
these statements. These risks and uncertainties are identified and
described in more detail in our filings with the Securities and
Exchange Commission, including our Annual Report on Form 10-K.
References:
- Data on file: D041679 Benchtop Stylet Advancement in a
Simulated Use Anatomical Model of NaviCurve™ Product Stylet/PICC
Assemblies. Bench testing may not be indicative of clinical
performance.
- ADHX-001612: Design History File Index for VPS Rhythm® DLX
- SystemSherlock 3CG+Tip Confirmation System for use with
Site~Rite 8 Ultrasound System Instructions for Use, Page 24.
Available here:
https://www.bd.com/assets/documents/PDH/SiteRite-8/0749067_Sherlock-3CGIFU.pdf
- Antimicrobial – In vitro data on file 2010; AVER-004371,
AVER-004483, AVAR-000427. No correlation between in vitro / in vivo
testing methods and clinical outcomes have currently been
ascertained. Antithrombogenic ‐ As compared to uncoated PICCs,
intravascular ovine model inoculated with Staph aureus:
AVAR‐000427. No correlation between in vitro / in vivo testing
methods and clinical outcomes have currently been ascertained.
Rx only
Contraindication:
Clinical assessment of the patient must be completed to ensure
no contraindications exist. The Arrowg+ard Blue Advance® PICC is
contraindicated in the following areas:
- Patients with known hypersensitivity to chlorhexidine
- In presence of device related
infections
- In presence of previous or current
thrombosis in the intended vessel or along the catheterized vessel
pathway.
No correlation between in vitro/in vivo testing methods and
clinical outcomes have currently been ascertained.
Tegaderm is a registered trademark of 3M or its affiliates.
Teleflex, the Teleflex logo, Arrow, Arrowg+ard Blue Advance,
Deknatel, LMA, NaviCurve, Pilling, QuikClot, Rusch, TipTracker,
UroLift, VPS Rhythm, and Weck are trademarks or registered
trademarks of Teleflex Incorporated or its affiliates, in the U.S.
and/or other countries. All other marks are the property of their
respective owners.
© 2023 Teleflex Incorporated. All rights reserved. MC-008720
Contacts:Teleflex Incorporated:Lawrence
KeuschVice President, Investor Relations and Strategy
Development
investors.teleflex.com610-948-2836
Teleflex (NYSE:TFX)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Teleflex (NYSE:TFX)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024